The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates

Memorias do Instituto Oswaldo Cruz

Volumn 107, Issue 3, 2012, Pages 433-436

  Mario, Débora Alves Nunes ^a   Denardi, Laura Bedin ^a   Bandeira, Laíssa Arévalo ^a   Antunes, Milene Silva ^b   Santurio, Janio Morais ^a   Severo, Luiz Carlos ^b   Alves, Sydney Hartz ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b Grupo Hospitalar Santa Casa de Misericordia   (Brazil)

Author keywords

Antifungal drug resistance; Candida glabrata; Echinocandins

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; LIPOPEPTIDE; MICAFUNGIN; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA GLABRATA; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FLUCONAZOLE; HUMANS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

CANDIDA; CANDIDA GLABRATA;

EID: 84860226646     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762012000300022     Document Type: Article

References (22)

1. Bennett JE, Izumikawa K, Marr KA 2004. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother 48: 1773-1777.
2. Borg-von Zepelin M, Zaschke K, Gross U, Monod M, Müller FM 2002. Effect of micafungin (FK463) on Candida albicans adherence to epithelial cells. Chemotherapy 48: 148-153.
3. Bormann AM, Morrison VA 2009. Review of the pharmacology and clinical studies of micafungin. Drug Des Devel Ther 3: 295-302.
4. Brielmaier BD, Casabar E, Kutzeborn CM, Mckinnon PS, Ritchie DJ 2008. Early clinical experience with anidulafungin at a large tertiary care medical center. Pharmacother 28: 64-73.
5. CLSI - Clinical and Laboratory Standards Institute 2008a. Reference method for broth dilution antifungal susceptibility testing yeasts. Approved standard M27-A3, 3rd ed., CLSI, Wayne, 25 pp.
6. CLSI - Clinical and Laboratory Standards Institute 2008b. Reference method for broth dilution antifungal susceptibility testing yeasts. Approved standard M27-S3, 3rd ed., CLSI, Wayne, 19 pp.
7. Colombo AL, Nucci M, Park BJ, Nouer AS, Arthington-Skaggs B, Matta DA, Warnock D, Morgan J, the Brazilian Network Candidemia Study 2006. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 44: 2816-2823.
8. Fekete-Forgács K, Gyurc L, Lenkey B 1999. Changes of virulence factors accompanying the phenomenon of induced fluconazole resistance in Candida albicans. Mycoses 43: 273-279.
9. Johnson LB, Kauffman CA 2003. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36: 630-637.
10. Kremery V, Barnes AJ 2002. Non-albicans Candida spp causing fungemia: pathogenicity and antifungal resistance. J Hosp Infect 50: 243-260.
11. Messer SA, Moet GJ, Kirb JT, Jones RN 2009. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp, Cryptococcus spp and Aspergillus spp: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol 47: 1942-1946.
12. Moudgal T, Little T, Boikov D, Vazquez JA 2005. Multiechinocandin and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 49: 767-769.
13. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH 2003. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 22: 651-655.
14. Park S, Kelly R, Kahn JN, Robles J, Hsu MJ, Register E, Li W, Vyas V, Fan H, Abruzzo G, Flattery A, Gill C, Chrebet G, Parent SA, Kurtz M, Teppler H, Douglas CM, Perlin DS 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida spp isolates. Antimicrob Agents Chemother 49: 3264-3273.
15. Perlin DS 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist Update 10: 121-130.
16. Pfaller MA, Diekema DJ 2004. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 42: 4419-4431.
17. Pfaller MA, Diekema DJ 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133-163.
18. Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S, Diekema DJ 2004. In vitro activities of voriconazole, posaconazole and fluconazole against 4,169 clinical isolates of Candida spp and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 48: 201-205.
19. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ 2007. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp tested by Clinical and Laboratory Standards Institute-recommended broth microdilution methods. J Clin Microbiol 45: 70-75.
20. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin SD, Alexander BD 2010. Breakthrough invasive candidiasis on micafungin. J Clin Microbiol 48: 2373-2380.
21. Posteraro B, Sanguinetti M, Fiori B, La Sorda M, Spanu T, Sanglard D, Fadda G 2006. Caspofungin activity against clinical isolates of azole cross-resistant Candida glabrata overexpressing efflux pump genes. J Antimicrob Chemother 58: 458-461.
22. Wiederhold NP, Lewis RE 2003. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs 12: 1313-1333.